RAYLA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Cresanto Global do?
Raymed Labs Ltd specializes in the manufacturing of a diverse range of pharmaceutical products including antibiotics, anti-inflammatories, and other medications for both human and veterinary use.
Who are the competitors of Cresanto Global?
Cresanto Global major competitors are Hemo Organic, Zyden Gentec, Fabino Enterprises, MPS Pharmaa, Kobo Biotech, Ganga Pharma., Secunderabad Health.. Market Cap of Cresanto Global is ₹1 Crs. While the median market cap of its peers are ₹5 Crs.
Is Cresanto Global financially stable compared to its competitors?
Cresanto Global seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Cresanto Global pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Cresanto Global latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Cresanto Global allocated its funds?
NA
How strong is Cresanto Global balance sheet?
Cresanto Global balance sheet is weak and might have solvency issues
Is the profitablity of Cresanto Global improving?
The profit is oscillating. The profit of Cresanto Global is -₹0.1 Crs for Mar 2024, -₹0.17 Crs for Mar 2023 and -₹0.08 Crs for Mar 2022
Is the debt of Cresanto Global increasing or decreasing?
Yes, The net debt of Cresanto Global is increasing. Latest net debt of Cresanto Global is ₹2.37 Crs as of Mar-25. This is greater than Mar-24 when it was ₹0 Crs.
Is Cresanto Global stock expensive?
Cresanto Global is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Cresanto Global is 0.0, while 3 year average PE is -0.01. Also latest EV/EBITDA of Cresanto Global is 0.0 while 3yr average is 107.
Has the share price of Cresanto Global grown faster than its competition?
Cresanto Global has given better returns compared to its competitors. Cresanto Global has grown at ~26.25% over the last 3yrs while peers have grown at a median rate of 0.0%
Is the promoter bullish about Cresanto Global?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 32.27% and last quarter promoter holding is 28.36%.
Are mutual funds buying/selling Cresanto Global?
There is Insufficient data to gauge this.